Survival outcomes of patients with advanced ovarian cancer receiving more than three cycles of neoadjuvant chemotherapy followed by interval cytoreductive surgery.
{"title":"Survival outcomes of patients with advanced ovarian cancer receiving more than three cycles of neoadjuvant chemotherapy followed by interval cytoreductive surgery.","authors":"Hanady Hegazy","doi":"10.5603/rpor.110814","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The objective of this study was to describe survival outcomes in patients with advanced ovarian cancer according to the number of neoadjuvant chemotherapy (NACT) cycles received and to explore their relation to cytoreduction and pathological response.</p><p><strong>Materials and methods: </strong>The study included 70 patients with advanced ovarian cancers presented to our center receiving neoadjuvant chemotherapy followed by interval debulking surgery and continuation of adjuvant treatment. Files of these patients were reviewed and data were extracted. Patients' outcomes were determined in terms of progression free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>The median age was 59 years. Median PFS and OS was 33 months. Univariate PFS and OS analysis revealed that optimal cytoreduction and achieving pathological complete response (PCR) significantly reduced the hazard of progression and death. However, the time interval between the end of NACT and surgical debulking and the number of adjuvant chemotherapy cycles received didn't affect the PFS or OS significantly. In multivariate analysis of PFS and OS, it was found that achieving PCR significantly affect the survival outcomes and is considered as independent prognostic and predictive factor for PFS and OS. The rate of optimal cytoreduction was significantly correlated with the number of NACTx cycles received.</p><p><strong>Conclusions: </strong>Our study suggests that increased number of neoadjuvant chemotherapy cycles in patients with advanced ovarian cancer don't adversely affect the survival outcomes and that the rate of optimal cytoreduction and achieving PCR significantly affect patients' survival outcomes. Rate of optimal cytoreduction significantly increased with the increased number of neoadjuvant chemotherapy received. Keywords: Ovarian cancer, neoadjuvant chemotherapy, interval debulking, optimal debulking.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 1","pages":"18-24"},"PeriodicalIF":2.0000,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046418/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reports of Practical Oncology and Radiotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/rpor.110814","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The objective of this study was to describe survival outcomes in patients with advanced ovarian cancer according to the number of neoadjuvant chemotherapy (NACT) cycles received and to explore their relation to cytoreduction and pathological response.
Materials and methods: The study included 70 patients with advanced ovarian cancers presented to our center receiving neoadjuvant chemotherapy followed by interval debulking surgery and continuation of adjuvant treatment. Files of these patients were reviewed and data were extracted. Patients' outcomes were determined in terms of progression free survival (PFS) and overall survival (OS).
Results: The median age was 59 years. Median PFS and OS was 33 months. Univariate PFS and OS analysis revealed that optimal cytoreduction and achieving pathological complete response (PCR) significantly reduced the hazard of progression and death. However, the time interval between the end of NACT and surgical debulking and the number of adjuvant chemotherapy cycles received didn't affect the PFS or OS significantly. In multivariate analysis of PFS and OS, it was found that achieving PCR significantly affect the survival outcomes and is considered as independent prognostic and predictive factor for PFS and OS. The rate of optimal cytoreduction was significantly correlated with the number of NACTx cycles received.
Conclusions: Our study suggests that increased number of neoadjuvant chemotherapy cycles in patients with advanced ovarian cancer don't adversely affect the survival outcomes and that the rate of optimal cytoreduction and achieving PCR significantly affect patients' survival outcomes. Rate of optimal cytoreduction significantly increased with the increased number of neoadjuvant chemotherapy received. Keywords: Ovarian cancer, neoadjuvant chemotherapy, interval debulking, optimal debulking.
期刊介绍：
Reports of Practical Oncology and Radiotherapy is an interdisciplinary bimonthly journal, publishing original contributions in clinical oncology and radiotherapy, as well as in radiotherapy physics, techniques and radiotherapy equipment. Reports of Practical Oncology and Radiotherapy is a journal of the Polish Society of Radiation Oncology, the Czech Society of Radiation Oncology, the Hungarian Society for Radiation Oncology, the Slovenian Society for Radiotherapy and Oncology, the Polish Study Group of Head and Neck Cancer, the Guild of Bulgarian Radiotherapists and the Greater Poland Cancer Centre, affiliated with the Spanish Society of Radiotherapy and Oncology, the Italian Association of Radiotherapy and the Portuguese Society of Radiotherapy - Oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
